CALLAN JMB INC
CJMBNASDAQTrading Snapshot
- Day Range
- $0.46 – $0.50
- 52-Week Range
- $0.38 – $5.61
- Volume (shares)
- 421,627
- Avg Volume (shares)
- —
- Shares Outstanding
- 5.8M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $6M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 0.6x
- EPS (TTM)
- $-1.97
- Dividend Yield
- —
- Dilution (1yr)
- −26.7%
CALLAN JMB INC
CJMB
StockOtter · stockotter.spaceAbout CALLAN JMB INC
Callan JMB Inc., operating primarily through its subsidiary Coldchain Technology Services, LLC, specializes in providing temperature-controlled logistics solutions specifically for the life sciences sector. The company's services include comprehensive frozen shipping capabilities essential for a wide range of sensitive biological and medical materials. These critical shipments encompass items such as personalized medicines, cell-based therapies, stem cells, cell lines, vaccines, diagnostic samples, reproductive materials (including semen, eggs, and embryos), cord blood, organs, biopharmaceutical products, infectious substances, and other vital commodities. Additionally, Callan JMB Inc. offers packaging services for other perishable (non-pharmaceutical) client goods, alongside technical support. The company was founded in 2006 and is based in Spring Branch, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Callan JMB to Break Ground on IV Bag Manufacturing Facility Fully Funded by Non-Dilutive and Non-Interest-Bearing Third-Party Partnership
The non-dilutive $16 million capital investment from a third party for Atlas Complex construction advances Callan JMB's pharmaceutical manufacturing strategy and strengthens its role in U.S. healthcare supply-chain prepa
Callan JMB Advances IV Bag Manufacturing Facility with Projected $450 Million in Annual Revenue
Planned $16 million facility at the Atlas Complex advances Callan JMB's pharmaceutical manufacturing strategy and strengthens its role in U.S. healthcare supply-chain preparedness SPRING BRANCH, Texas, Oct. 20, 2026 (GLO
Callan JMB Advances U.S. Pharmaceutical Manufacturing at the Atlas Complex and Expands into North American Equipment Distribution and Assembly
Approximately $28 million in planned TRUKING equipment advances domestic manufacturing capacity, strengthens the Company's preparedness strategy, and supports new commercial opportunities
Callan Power to Acquire Williston Basin Non-Operated Oil and Gas Assets with $48 Million Proved PV-10 and $83 Million 3P PV-10 from The Pfanenstiel Company, Significantly Expanding Energy Assets
Acquisition includes interests across 377 producing wells, approximately 150 BOE/day of current net production, and 27 additional wells in process, with $48 million of proved PV-10 and an illustrative 21% unlevered cash
Callan JMB Designates Andy Weigman to Join Callan Power's Oil and Gas Development Efforts; Weigman Brings Experience on More Than $1 Billion in Sourced Acquisition Opportunities and Extensive Williston Basin Operational Expertise
Weigman brings 14 years of Williston Basin experience, including nine years at Northern Oil and Gas, and has sourced potential acquisition opportunities across more than 900 wells The appointment will reunite Weigman wit
Callan JMB Retains Northern Oil and Gas Founder Michael Reger as President of Callan Power; Northern Oil and Gas Now Valued at Approximately $2.9 Billion
Mr. Reger brings proven public-company, capital-markets, and energy-sector leadership to advance Callan Power's domestic manufacturing and critical electrical-infrastructure strategy